

- **Name:** Kyoung Eun Lee
 - **Current Position & Affiliation:** Associate professor/Ewha Womans University
Mokdong Hospital
 - **Country:** Republic of Korea
-

• **Educational Background:**

- March 1990 - February 1996: M.D. Degree from School of Medicine, Ewha Womans University
- March 1999 - February 2001: Master's degree from School of Medicine, Ewha Womans University
- September 2004 – February 2007: Ph.D. degree from School of Medicine, Seoul National University

• **Professional Experience:**

- March 1996 - February 1997 Internship: Ewha Womans University Hospital
- March 1997 - February 2001 Residency Training: Department of Internal Medicine, Ewha Womans University Hospital
- March 2001 – February: Clinical Fellowship at Division of Hematology-Oncology, Dept. of Internal Medicine, Ewha Womans University Hospital
- March 2002 – February 2003: Clinical Fellowship at Division of Hematology-Oncology, Samsung Medical Center
- March 2003 – September 2003: Research Instructor of division of Hematology and Oncology, Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University
- Oct 2010 – Aug 2011: Post-doc Fellowship, Oncological Science dept. Mount Sinai Medical School, New York, NY, USA
- October 2003 – Present: Associate professor, division of Hematology and Oncology, Internal Medicine, Ewha Womans University Mokdong Hospital

• **Professional Organizations:**

N/A

• **Main Scientific Publications:**

1. Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: the Concept of Chemo-Selection (KCSG HN13-01) Cancer Res Treat. 2021 Apr 27. doi: 10.4143/crt.2020.1329. Online ahead of print.
2. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12
3. Cancer Res Treat . 2021 Jul;53(3):671-677. doi: 10.4143/crt.2020.824. Epub 2020 Dec 7.
4. Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13). Volume 142, June 2021, 155487

15th Annual Meeting of the Korean Society of Medical Oncology & 2022 International Conference

5. Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase II Trial (KCSG-BR 15-10). *Cancers (Basel)*. 2020 Nov 5;12(11):3265. doi: 10.3390/cancers12113265.
6. Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.
7. *J Cancer Res Clin Oncol*. 2020 Dec;146(12):3359-3369. doi: 10.1007/s00432-020-03316-5.
8. Peroxiredoxin 3 Has Important Roles on Arsenic Trioxide Induced Apoptosis in Human Acute Promyelocytic Leukemia Cell Line via Hyperoxidation of Mitochondrial Specific Reactive Oxygen Species. *Mol. Cells* 2020; 43(9): 813-820
9. Tumor genomic profiling guides metastatic gastric cancer patients to targeted treatment: The VIKTORY Umbrella Trial. *Cancer Discov*. 2019 Jul 17.
10. Palbociclib Plus Exemestane With Gonadotropin-Releasing Hormone Agonist Versus Capecitabine in Premenopausal Women With Hormone Receptor-Positive, HER2-negative Metastatic Breast Cancer (KCSG-BR15-10): A Multicentre, Open-Label, Randomised, Phase 2 Trial. *Lancet Oncol* . 2019 Dec;20(12):1750-1759.
11. Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). **Gastric Cancer**. 2018.9. 21(5):819-830. The enhanced tumor inhibitory effects of gefitinib and L-ascorbic acid combination therapy in non-small cell lung cancer cells. *ONCOLOGY LETTERS* 14: 276-282, 2017.7